Jesse Dawson
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Previous Organizations / Institutes
The organizations / institutes from the scholar's other articles in the past ten years
Research Subjects
Jesse Dawson has a total of 732 co-authors. Here are the top co-authors by number of shared publications:
Matthew Walters
School of Medicine, Dentistry and Nursing, College of Medical, Veterinary & Life Sciences University of Glasgow Glasgow UK
11 shared publications- Azmil H. Abdul-Rahima
Liverpool Centre for Cardiovascular Science at University of Liverpool, Liverpool John Moores University and Liverpool Heart & Chest Hospital, Liverpool, UK 1
8 shared publications Kirsten Forbes
Department of Neuroradiology, Institute of Neurological Sciences Queen Elizabeth University Hospital Glasgow UK
7 shared publications- Urs Fischer
Department of Neurology, University Hospital Bern and University of Bern, Switzerland (U.F.).
7 shared publications - Alastair John Stewart Webb
Department of Brain Sciences, Imperial College London, London, UK
6 shared publications - Daniel Strbian
Department of Neurology, Helsinki University Hospital and University of Helsinki , Helsinki
6 shared publications
Latest Publications
- 14 July 2026
- Published by Wolters Kluwer Health in Neurology
- Vol. 107 (3) , e218298
Two-Year Retention of Benefits After Paired Vagus Nerve Stimulation in Stroke: Follow-Up of the VNS-REHAB Randomized Clinical Trial.
Vagus nerve stimulation (VNS) paired with rehabilitation improves short-term upper extremity (UE) function in people with chronic ischemic stroke. Because sustained improvements are needed for people with stroke, we examined the long-term effects of Paired VNS on impairment, activity, participation, and quality of life. This is a post hoc analysis of 2-year data of the triple-blind, sham-controlled, randomized VNS-REHAB pivotal trial. After receiving the full therapeutic protocol with either real (Active) or sham (Control) VNS, participants continued self-activated active stimulation for at least 2 years. The Fugl-Meyer Assessment-Upper Extremity (FMA-UE), Wolf Motor Function Test (WMFT), participation, and quality of life outcomes were assessed at multiple time points. Pooled 2-year outcome data were available from 49 participants. At the 2-year point, FMA-UE scores improved 7.51 points (95% CI 5.80-9.22; p < 0.001), and WFMT scores improved 0.63 points (0.50-0.75; p < 0.001) from baseline. There were significant improvements from baseline in 5 of 7 participation and quality of life measures at 2 years. Improvements were retained at 3 years among a subset of participants (n = 16). The sustained improvements in UE impairment and function for at least 2 years make this an important treatment option for a defined subset of individuals with chronic arm and hand deficits after ischemic stroke. ClinicalTrials.gov/study/NCT03131960.
- 14 July 2026
- Published by Wolters Kluwer Health in Neurology
- Vol. 107 (3) , e218298
Two-Year Retention of Benefits After Paired Vagus Nerve Stimulation in Stroke: Follow-Up of the VNS-REHAB Randomized Clinical Trial.
Vagus nerve stimulation (VNS) paired with rehabilitation improves short-term upper extremity (UE) function in people with chronic ischemic stroke. Because sustained improvements are needed for people with stroke, we examined the long-term effects of Paired VNS on impairment, activity, participation, and quality of life. This is a post hoc analysis of 2-year data of the triple-blind, sham-controlled, randomized VNS-REHAB pivotal trial. After receiving the full therapeutic protocol with either real (Active) or sham (Control) VNS, participants continued self-activated active stimulation for at least 2 years. The Fugl-Meyer Assessment-Upper Extremity (FMA-UE), Wolf Motor Function Test (WMFT), participation, and quality of life outcomes were assessed at multiple time points. Pooled 2-year outcome data were available from 49 participants. At the 2-year point, FMA-UE scores improved 7.51 points (95% CI 5.80-9.22; p < 0.001), and WFMT scores improved 0.63 points (0.50-0.75; p < 0.001) from baseline. There were significant improvements from baseline in 5 of 7 participation and quality of life measures at 2 years. Improvements were retained at 3 years among a subset of participants (n = 16). The sustained improvements in UE impairment and function for at least 2 years make this an important treatment option for a defined subset of individuals with chronic arm and hand deficits after ischemic stroke. ClinicalTrials.gov/study/NCT03131960.
- 1 February 2026
- Published by Wolters Kluwer Health in Stroke
- Vol. 57 (2) , 381-390
Quality of Evidence in European Stroke Organisation and American Heart Association Stroke Guidelines
BACKGROUND: Evidence-based practice relies on clinical guidelines, whose recommendations depend on the quality, relevance, and validity of supporting research. We evaluated the class/strength and level of evidence (LOE) or quality of evidence (QOE) supporting American Heart Association/American Stroke Association and European Stroke Organisation guideline recommendations, and examined temporal changes in LOE. METHODS: Stroke guidelines from American Heart Association/American Stroke Association (1995–2025) and European Stroke Organisation (2014–2025) were identified through society websites and EMBASE/MEDLINE. Eligible documents contained recommendations with class/strength and LOE/QOE. Consensus statements were excluded. Since 2006, American Heart Association/American Stroke Association has classified LOE as A (multiple or large randomized-controlled trials), B (single trial or observational studies), or C (expert opinion). European Stroke Organisation applies the Grading of Recommendations Assessment, Development, and Evaluation system (high, moderate, low, and very low QOE). RESULTS: Across 1102 recommendations in 9 current American Heart Association/American Stroke Association stroke guidelines, 156 (14.2%) were supported by LOE A, 559 (50.7%) by LOE B, and 387 (35.1%) by LOE C. Of 407 class I recommendations (ie, should do), and 117 class III recommendations (ie, should not do), 116 (22.1%), 258 (49.2%), and 150 (28.6%) were supported by LOE A, B, and C, respectively. Although the number of recommendations increased across guideline updates (median, 22 [interquartile range, 25th–75th percentiles, 18.0–42.0]), the proportion supported by LOE A declined (median, −4.6% [interquartile range, −7.8 to −0.8]). Across 260 recommendations in 30 European Stroke Organisation guidelines, 19 (7.3%) were supported by high, 62 (23.8%) by moderate, 81 (31.2%) by low, and 98 (37.7%) by very low QOE. Among 90 strong recommendations, 18 (20.0%) were supported by high QOE, and 66.7% of guideline topics had no recommendations supported by high QOE. There was insufficient evidence to make recommendations for 123 (32.7%) clinical questions. CONCLUSIONS: Due to limited randomized data for many important clinical questions, most stroke guideline recommendations are based on low-to-moderate–quality evidence. These findings emphasize the need to improve the funding, design, and delivery of efficient, patient-focused clinical trials.
- 1 February 2026
- Published by Wolters Kluwer Health in Stroke
- Vol. 57 (2) , 381-390
Quality of Evidence in European Stroke Organisation and American Heart Association Stroke Guidelines
BACKGROUND: Evidence-based practice relies on clinical guidelines, whose recommendations depend on the quality, relevance, and validity of supporting research. We evaluated the class/strength and level of evidence (LOE) or quality of evidence (QOE) supporting American Heart Association/American Stroke Association and European Stroke Organisation guideline recommendations, and examined temporal changes in LOE. METHODS: Stroke guidelines from American Heart Association/American Stroke Association (1995–2025) and European Stroke Organisation (2014–2025) were identified through society websites and EMBASE/MEDLINE. Eligible documents contained recommendations with class/strength and LOE/QOE. Consensus statements were excluded. Since 2006, American Heart Association/American Stroke Association has classified LOE as A (multiple or large randomized-controlled trials), B (single trial or observational studies), or C (expert opinion). European Stroke Organisation applies the Grading of Recommendations Assessment, Development, and Evaluation system (high, moderate, low, and very low QOE). RESULTS: Across 1102 recommendations in 9 current American Heart Association/American Stroke Association stroke guidelines, 156 (14.2%) were supported by LOE A, 559 (50.7%) by LOE B, and 387 (35.1%) by LOE C. Of 407 class I recommendations (ie, should do), and 117 class III recommendations (ie, should not do), 116 (22.1%), 258 (49.2%), and 150 (28.6%) were supported by LOE A, B, and C, respectively. Although the number of recommendations increased across guideline updates (median, 22 [interquartile range, 25th–75th percentiles, 18.0–42.0]), the proportion supported by LOE A declined (median, −4.6% [interquartile range, −7.8 to −0.8]). Across 260 recommendations in 30 European Stroke Organisation guidelines, 19 (7.3%) were supported by high, 62 (23.8%) by moderate, 81 (31.2%) by low, and 98 (37.7%) by very low QOE. Among 90 strong recommendations, 18 (20.0%) were supported by high QOE, and 66.7% of guideline topics had no recommendations supported by high QOE. There was insufficient evidence to make recommendations for 123 (32.7%) clinical questions. CONCLUSIONS: Due to limited randomized data for many important clinical questions, most stroke guideline recommendations are based on low-to-moderate–quality evidence. These findings emphasize the need to improve the funding, design, and delivery of efficient, patient-focused clinical trials.
- Open Access
- 1 January 2026
- Published by Oxford University Press (OUP) in European Stroke Journal
- Vol. 11 (1)
Once- versus twice-daily direct oral anticoagulants after ischemic stroke in atrial fibrillation – A post-hoc analysis of the ELAN trial
Introduction: Whether the risk-benefit profile of once-daily versus twice-daily direct oral anticoagulants (DOAC) differs after atrial fibrillation(AF)-associated ischemic stroke is unclear. We explored this in a post-hoc analysis of ELAN trial data (NCT03148457). Patients and methods: We compared the risk of the primary outcome (recurrent ischemic stroke, systemic embolism, intracranial hemorrhage (ICH), major extracranial bleeding, vascular death) from treatment initiation to the trial’s 90-day follow-up in participants treated with once-daily or twice-daily DOAC after AF-associated stroke using Firth’s logistic and Cox proportional hazards regression in unadjusted, inverse-probability-of-treatment-weighted and augmented-inverse-probability-weighted models to address confounding. Secondary outcomes were the primary outcome components and non-major bleeding. We calculated the net clinical benefit (NCB) of twice-daily over once-daily DOAC by subtracting the weighted rate of excess bleeding attributable to twice-daily DOAC from the rate of excess ischemic events possibly prevented by twice-daily DOAC. Results: We analyzed 1890/2013 (94%) participants (median age 77 years, 45% female), of whom 384 (20%) received once-daily and 1506 (80%) twice-daily DOAC. The primary outcome occurred in 64 (3.4%) participants, and did not differ between DOAC types in logistic (ORunadjusted 0.89 (95% CI 0.50–1.66); ORweighted 1.34 (0.71–2.79); ORaugmented 1.45 (0.81–3.21); twice-daily vs once-daily DOAC) nor in Cox models. We identified no clear differences in any secondary outcome. NCB analysis revealed a near-neutral net effect of twice-daily versus once-daily DOAC (+0.28 to +0.67 weighted events possibly prevented/100 person-months for ICH weights 1.5–3.3). Discussion and conclusion: The risk-benefit profile of once-daily versus twice-daily DOAC after AF-associated ischemic stroke does not seem to differ.
- 1 January 2026
- Published by Oxford University Press (OUP) in European Stroke Journal
- Vol. 11 (1)
Open AccessOnce- versus twice-daily direct oral anticoagulants after ischemic stroke in atrial fibrillation – A post-hoc analysis of the ELAN trial
Introduction: Whether the risk-benefit profile of once-daily versus twice-daily direct oral anticoagulants (DOAC) differs after atrial fibrillation(AF)-associated ischemic stroke is unclear. We explored this in a post-hoc analysis of ELAN trial data (NCT03148457). Patients and methods: We compared the risk of the primary outcome (recurrent ischemic stroke, systemic embolism, intracranial hemorrhage (ICH), major extracranial bleeding, vascular death) from treatment initiation to the trial’s 90-day follow-up in participants treated with once-daily or twice-daily DOAC after AF-associated stroke using Firth’s logistic and Cox proportional hazards regression in unadjusted, inverse-probability-of-treatment-weighted and augmented-inverse-probability-weighted models to address confounding. Secondary outcomes were the primary outcome components and non-major bleeding. We calculated the net clinical benefit (NCB) of twice-daily over once-daily DOAC by subtracting the weighted rate of excess bleeding attributable to twice-daily DOAC from the rate of excess ischemic events possibly prevented by twice-daily DOAC. Results: We analyzed 1890/2013 (94%) participants (median age 77 years, 45% female), of whom 384 (20%) received once-daily and 1506 (80%) twice-daily DOAC. The primary outcome occurred in 64 (3.4%) participants, and did not differ between DOAC types in logistic (ORunadjusted 0.89 (95% CI 0.50–1.66); ORweighted 1.34 (0.71–2.79); ORaugmented 1.45 (0.81–3.21); twice-daily vs once-daily DOAC) nor in Cox models. We identified no clear differences in any secondary outcome. NCB analysis revealed a near-neutral net effect of twice-daily versus once-daily DOAC (+0.28 to +0.67 weighted events possibly prevented/100 person-months for ICH weights 1.5–3.3). Discussion and conclusion: The risk-benefit profile of once-daily versus twice-daily DOAC after AF-associated ischemic stroke does not seem to differ.
- 1 January 2026
- Published by Wolters Kluwer Health in Stroke
- Vol. 57 (1) , 77-88
Risk of Early Recurrent Stroke and Thrombotic Events After Reperfusion Therapy in Acute Ischemic Stroke: A Meta-Analysis
BACKGROUND: Following an acute ischemic stroke, the risk of recurrent stroke is highest in the first 90 days. It is unclear whether this risk is altered by reperfusion therapy. In this meta-analysis, we aim to evaluate the risk of early recurrent stroke and other nonstroke thrombotic events postreperfusion therapy in acute ischemic stroke. METHODS: In this meta-analysis, randomized controlled trials (RCTs) were included in adults aged 18 years or older with acute ischemic stroke, comparing reperfusion treatment with best medical management (MED). We searched PUBMED, Embase, Cochrane Library, and Web of Science databases. The studies were grouped into endovascular thrombectomy (EVT) versus MED and intravenous thrombolysis versus MED. We performed a meta-analysis using a random-effects model (restricted maximum likelihood) to estimate the log risk ratio (RR) of early recurrent stroke and nonstroke thrombotic events (NSTE)—including myocardial infarction, acute coronary syndrome, deep vein thrombosis, pulmonary embolism, and peripheral embolism—after reperfusion therapy compared with MED at 90 days after symptom onset. This study is registered with PROSPERO (The International Prospective Register of Systematic Reviews). RESULTS: A total of 15 RCTs (n=4898) comparing EVT versus MED observed no difference in early recurrent stroke (5.5%, 143/2618 versus 4.5%, 102/2280; RR, 1.2 [95% CI, 0.9–1.6]). Nine RCTs (n=7193) comparing intravenous thrombolysis versus MED observed no difference in early recurrent stroke (2%, 73/3615 versus 1.8%, 66/3578; RR, 1.1 [95% CI, 0.8–1.5]). Fourteen RCTs (n=4033) comparing EVT versus MED reported NSTE. There was no difference in NSTE in the EVT arm (3.1%, 62/2024 versus 3.1%, 62/2009; RR, 1 [95% CI, 0.7–1.4]). Five RCTs (n=4961) comparing intravenous thrombolysis versus MED observed no difference in NSTE (2%, 51/2479 versus 2.2%, 54/2482; RR, 0.9 [95% CI, 0.6–1.4]). CONCLUSIONS: Reperfusion therapies (EVT±intravenous thrombolysis) in acute ischemic stroke within 24 hours of symptom onset were not associated with increased recurrent stroke or NSTE within 90 days compared with best medical therapy. REGISTRATION: URL: https://www.crd.york.ac.uk/PROSPERO/ ; Unique identifier: CRD42024542020.
- 1 January 2026
- Published by Wolters Kluwer Health in Stroke
- Vol. 57 (1) , 77-88
Risk of Early Recurrent Stroke and Thrombotic Events After Reperfusion Therapy in Acute Ischemic Stroke: A Meta-Analysis
BACKGROUND: Following an acute ischemic stroke, the risk of recurrent stroke is highest in the first 90 days. It is unclear whether this risk is altered by reperfusion therapy. In this meta-analysis, we aim to evaluate the risk of early recurrent stroke and other nonstroke thrombotic events postreperfusion therapy in acute ischemic stroke. METHODS: In this meta-analysis, randomized controlled trials (RCTs) were included in adults aged 18 years or older with acute ischemic stroke, comparing reperfusion treatment with best medical management (MED). We searched PUBMED, Embase, Cochrane Library, and Web of Science databases. The studies were grouped into endovascular thrombectomy (EVT) versus MED and intravenous thrombolysis versus MED. We performed a meta-analysis using a random-effects model (restricted maximum likelihood) to estimate the log risk ratio (RR) of early recurrent stroke and nonstroke thrombotic events (NSTE)—including myocardial infarction, acute coronary syndrome, deep vein thrombosis, pulmonary embolism, and peripheral embolism—after reperfusion therapy compared with MED at 90 days after symptom onset. This study is registered with PROSPERO (The International Prospective Register of Systematic Reviews). RESULTS: A total of 15 RCTs (n=4898) comparing EVT versus MED observed no difference in early recurrent stroke (5.5%, 143/2618 versus 4.5%, 102/2280; RR, 1.2 [95% CI, 0.9–1.6]). Nine RCTs (n=7193) comparing intravenous thrombolysis versus MED observed no difference in early recurrent stroke (2%, 73/3615 versus 1.8%, 66/3578; RR, 1.1 [95% CI, 0.8–1.5]). Fourteen RCTs (n=4033) comparing EVT versus MED reported NSTE. There was no difference in NSTE in the EVT arm (3.1%, 62/2024 versus 3.1%, 62/2009; RR, 1 [95% CI, 0.7–1.4]). Five RCTs (n=4961) comparing intravenous thrombolysis versus MED observed no difference in NSTE (2%, 51/2479 versus 2.2%, 54/2482; RR, 0.9 [95% CI, 0.6–1.4]). CONCLUSIONS: Reperfusion therapies (EVT±intravenous thrombolysis) in acute ischemic stroke within 24 hours of symptom onset were not associated with increased recurrent stroke or NSTE within 90 days compared with best medical therapy. REGISTRATION: URL: https://www.crd.york.ac.uk/PROSPERO/ ; Unique identifier: CRD42024542020.
- Open Access
- 11 December 2025
- Published by Oxford University Press (OUP) in European Stroke Journal
- Vol. 11 (1)
Genotype-phenotype correlations in a Scottish CADASIL cohort and comparison with sporadic small vessel disease
Introduction: CADASIL is a monogenic inherited cerebral small vessel disease (SVD) caused by a mutation affecting the NOTCH3 gene. Mutation location appears to influence disease severity. We investigated the hypothesis that mutation location modifies phenotype by comparing a CADASIL population stratified by mutation site risk with a cohort of older people with sporadic SVD. Patients and methods: We included adults with CADASIL and control group from the XILO-FIST trial. We recorded age at first stroke, white matter hyperintensity (WMH) volume, lacunes, cerebral microbleeds and other clinical biomarkers. We divided the CADASIL cohort into (1) two groups NOTCH3 mutations affecting epidermal growth factor-like repeat (EGFr) domains 1–6 (proximal) and EGFr domains 7–34 (distal); and (2) three groups; low, medium and high-risk based on a proposed three-tiered risk stratification. Results: The CADASIL cohort included 129 people, 57 (44.2%) male, mean age 47.5 ± 11.7 years. The sporadic SVD cohort included 460 people, 317 (68.9%) male, mean age 65.7 ± 8.7 years. The CADASIL proximal group were imaged at younger age, but fewer had hypertension (14.3% v 38.1%) compared to distal mutations. Lacune count and WMH volume differed between low, medium and high-risk CADASIL mutations, and sporadic SVD. Percentage progression of WMH volume was higher in proximal CADASIL (0.26%), than distal CADASIL (0.14%) which was higher than sporadic SVD (0.05%), p < 0.001. Discussion and conclusion: Proximal CADASIL mutations average more extensive WMH, higher lacune count and experienced first stroke at younger age than those with distal mutations. Both groups showed imaging differences compared to sporadic SVD.
- 11 December 2025
- Published by Oxford University Press (OUP) in European Stroke Journal
- Vol. 11 (1)
Open AccessGenotype-phenotype correlations in a Scottish CADASIL cohort and comparison with sporadic small vessel disease
Introduction: CADASIL is a monogenic inherited cerebral small vessel disease (SVD) caused by a mutation affecting the NOTCH3 gene. Mutation location appears to influence disease severity. We investigated the hypothesis that mutation location modifies phenotype by comparing a CADASIL population stratified by mutation site risk with a cohort of older people with sporadic SVD. Patients and methods: We included adults with CADASIL and control group from the XILO-FIST trial. We recorded age at first stroke, white matter hyperintensity (WMH) volume, lacunes, cerebral microbleeds and other clinical biomarkers. We divided the CADASIL cohort into (1) two groups NOTCH3 mutations affecting epidermal growth factor-like repeat (EGFr) domains 1–6 (proximal) and EGFr domains 7–34 (distal); and (2) three groups; low, medium and high-risk based on a proposed three-tiered risk stratification. Results: The CADASIL cohort included 129 people, 57 (44.2%) male, mean age 47.5 ± 11.7 years. The sporadic SVD cohort included 460 people, 317 (68.9%) male, mean age 65.7 ± 8.7 years. The CADASIL proximal group were imaged at younger age, but fewer had hypertension (14.3% v 38.1%) compared to distal mutations. Lacune count and WMH volume differed between low, medium and high-risk CADASIL mutations, and sporadic SVD. Percentage progression of WMH volume was higher in proximal CADASIL (0.26%), than distal CADASIL (0.14%) which was higher than sporadic SVD (0.05%), p < 0.001. Discussion and conclusion: Proximal CADASIL mutations average more extensive WMH, higher lacune count and experienced first stroke at younger age than those with distal mutations. Both groups showed imaging differences compared to sporadic SVD.
- Open Access
- 22 September 2025
- Published by Wiley in Annals of Clinical and Translational Neurology
- Vol. 13 (1) , 14-20
Change in Cognition Following Ischaemic Stroke
Objective: Cognitive decline can occur following ischaemic stroke. How cognition changes over time and associations with cognitive change are poorly understood. This study aimed to explore these issues over 2 years following ischaemic stroke. Methods: This analysis used data from the XILO‐FIST study, a clinical trial of allopurinol versus placebo in people with ischaemic stroke according to Tissue‐Based Definition. Participants underwent clinical assessment, brain MRI at baseline, and Montreal Cognitive Assessment (MoCA) at baseline, year 1 and year 2. We defined cognitive impairment as a MoCA score < 26 and cognitive change as a difference in MoCA score of 2 points or more at year 1 or year 2 after randomisation. Associations with cognitive impairment and cognitive change were assessed by univariable analysis and multiple logistic regression. Results: Three hundred and sixty participants with complete MoCA data were included. Mean age was 65.4 (SD 8.36) years, and mean baseline MoCA score was 26.4 (SD 2.7). Seventy‐seven participants had second‐year cognitive improvement. Eighty‐four had second‐year cognitive decline. After adjustment for age and education year, second‐year cognitive improvement was associated with smaller brain volume, lower albumin level, smoking and greater white‐matter hyperintensity, and second‐year cognitive decline was associated with peripheral arterial disease, higher cholesterol level, small‐vessel stroke and greater white‐matter hyperintensity. Interpretation: Cognition is dynamic following stroke, with different patterns of change. Brain reserve and vascular risk factors relate to later post‐stroke cognitive change. This complex nature of cognitive trajectory has implications for cognitive rehabilitation provision and cognitive impairment detection after stroke.
- 22 September 2025
- Published by Wiley in Annals of Clinical and Translational Neurology
- Vol. 13 (1) , 14-20
Open AccessChange in Cognition Following Ischaemic Stroke
Objective: Cognitive decline can occur following ischaemic stroke. How cognition changes over time and associations with cognitive change are poorly understood. This study aimed to explore these issues over 2 years following ischaemic stroke. Methods: This analysis used data from the XILO‐FIST study, a clinical trial of allopurinol versus placebo in people with ischaemic stroke according to Tissue‐Based Definition. Participants underwent clinical assessment, brain MRI at baseline, and Montreal Cognitive Assessment (MoCA) at baseline, year 1 and year 2. We defined cognitive impairment as a MoCA score < 26 and cognitive change as a difference in MoCA score of 2 points or more at year 1 or year 2 after randomisation. Associations with cognitive impairment and cognitive change were assessed by univariable analysis and multiple logistic regression. Results: Three hundred and sixty participants with complete MoCA data were included. Mean age was 65.4 (SD 8.36) years, and mean baseline MoCA score was 26.4 (SD 2.7). Seventy‐seven participants had second‐year cognitive improvement. Eighty‐four had second‐year cognitive decline. After adjustment for age and education year, second‐year cognitive improvement was associated with smaller brain volume, lower albumin level, smoking and greater white‐matter hyperintensity, and second‐year cognitive decline was associated with peripheral arterial disease, higher cholesterol level, small‐vessel stroke and greater white‐matter hyperintensity. Interpretation: Cognition is dynamic following stroke, with different patterns of change. Brain reserve and vascular risk factors relate to later post‐stroke cognitive change. This complex nature of cognitive trajectory has implications for cognitive rehabilitation provision and cognitive impairment detection after stroke.
- Open Access
- 1 September 2025
- Published by Oxford University Press (OUP) in European Stroke Journal
- Vol. 10 (3) , 961-967
Impact of central adjudication of the score on the modified Rankin Scale in an international, randomized, acute stroke trial
Introduction: The modified Rankin Scale (mRS) is the most frequently used primary outcome measure in acute stroke research despite significant interobserver variability in assigning grades. We assessed the use of central blinded adjudication of the mRS based on a video recording of an interview in the PRECIOUS trial. Patients and methods: PRECIOUS was an international, randomized, open-label, clinical trial with blinded outcome assessment of preventive treatment with metoclopramide, paracetamol, and ceftriaxone in elderly patients with acute stroke. Trained local investigators interviewed patients or their representatives and graded functional outcome at 90 days after stroke with the mRS. In each participating country, a video recording of the interview was assessed by three blinded, independent adjudicators. The primary outcome of the present substudy was interobserver agreement between the local mRS score and the median score of the three central adjudicators for patients alive at 90 days, assessed with Cohen’s kappa and quadratic weighted kappa statistics. The difference between treatment effect estimates based on local and central adjudication was a secondary outcome. Results: Of 1493 patients enrolled in PRECIOUS, 1471 were included in this analysis. At 90 days, 1117 patients (75.9%) were alive and had both a central and local assessment; 28 participants did not have a central mRS score. Interobserver agreement was seen in 829 (74.2%) patients and was substantial (kappa of 0.68; 95% CI 0.65–0.71). Disagreement occurred more often in patients with a central mRS score of 0–2 (OR 2.24; 95% CI 1.14–4.24). Treatment effects were neutral for all three study drugs and did not differ between central and local adjudication. Discussion and conclusion: Central adjudication of the mRS based on a video recording is feasible in a large international, randomized stroke trial. This ensures blinding of the outcome assessment. In this neutral trial, the impact of central adjudication on the precision of effect size estimates could not be assessed.
- 1 September 2025
- Published by Oxford University Press (OUP) in European Stroke Journal
- Vol. 10 (3) , 961-967
Open AccessImpact of central adjudication of the score on the modified Rankin Scale in an international, randomized, acute stroke trial
Introduction: The modified Rankin Scale (mRS) is the most frequently used primary outcome measure in acute stroke research despite significant interobserver variability in assigning grades. We assessed the use of central blinded adjudication of the mRS based on a video recording of an interview in the PRECIOUS trial. Patients and methods: PRECIOUS was an international, randomized, open-label, clinical trial with blinded outcome assessment of preventive treatment with metoclopramide, paracetamol, and ceftriaxone in elderly patients with acute stroke. Trained local investigators interviewed patients or their representatives and graded functional outcome at 90 days after stroke with the mRS. In each participating country, a video recording of the interview was assessed by three blinded, independent adjudicators. The primary outcome of the present substudy was interobserver agreement between the local mRS score and the median score of the three central adjudicators for patients alive at 90 days, assessed with Cohen’s kappa and quadratic weighted kappa statistics. The difference between treatment effect estimates based on local and central adjudication was a secondary outcome. Results: Of 1493 patients enrolled in PRECIOUS, 1471 were included in this analysis. At 90 days, 1117 patients (75.9%) were alive and had both a central and local assessment; 28 participants did not have a central mRS score. Interobserver agreement was seen in 829 (74.2%) patients and was substantial (kappa of 0.68; 95% CI 0.65–0.71). Disagreement occurred more often in patients with a central mRS score of 0–2 (OR 2.24; 95% CI 1.14–4.24). Treatment effects were neutral for all three study drugs and did not differ between central and local adjudication. Discussion and conclusion: Central adjudication of the mRS based on a video recording is feasible in a large international, randomized stroke trial. This ensures blinding of the outcome assessment. In this neutral trial, the impact of central adjudication on the precision of effect size estimates could not be assessed.
- Open Access
- 11 August 2025
- Published by Oxford University Press (OUP) in European Stroke Journal
Once- versus twice-daily direct oral anticoagulants after ischemic stroke in atrial fibrillation – A post-hoc analysis of the ELAN trial
Introduction: Whether the risk-benefit profile of once-daily versus twice-daily direct oral anticoagulants (DOAC) differs after atrial fibrillation(AF)-associated ischemic stroke is unclear. We explored this in a post-hoc analysis of ELAN trial data (NCT03148457). Patients and methods: We compared the risk of the primary outcome (recurrent ischemic stroke, systemic embolism, intracranial hemorrhage (ICH), major extracranial bleeding, vascular death) from treatment initiation to the trial’s 90-day follow-up in participants treated with once-daily or twice-daily DOAC after AF-associated stroke using Firth’s logistic and Cox proportional hazards regression in unadjusted, inverse-probability-of-treatment-weighted and augmented-inverse-probability-weighted models to address confounding. Secondary outcomes were the primary outcome components and non-major bleeding. We calculated the net clinical benefit (NCB) of twice-daily over once-daily DOAC by subtracting the weighted rate of excess bleeding attributable to twice-daily DOAC from the rate of excess ischemic events possibly prevented by twice-daily DOAC. Results: We analyzed 1890/2013 (94%) participants (median age 77 years, 45% female), of whom 384 (20%) received once-daily and 1506 (80%) twice-daily DOAC. The primary outcome occurred in 64 (3.4%) participants, and did not differ between DOAC types in logistic (OR unadjusted 0.89 (95% CI 0.50–1.66); OR weighted 1.34 (0.71–2.79); OR augmented 1.45 (0.81–3.21); twice-daily vs once-daily DOAC) nor in Cox models. We identified no clear differences in any secondary outcome. NCB analysis revealed a near-neutral net effect of twice-daily versus once-daily DOAC (+0.28 to +0.67 weighted events possibly prevented/100 person-months for ICH weights 1.5–3.3). Discussion and conclusion: The risk-benefit profile of once-daily versus twice-daily DOAC after AF-associated ischemic stroke does not seem to differ.
- 11 August 2025
- Published by Oxford University Press (OUP) in European Stroke Journal
Open AccessOnce- versus twice-daily direct oral anticoagulants after ischemic stroke in atrial fibrillation – A post-hoc analysis of the ELAN trial
Introduction: Whether the risk-benefit profile of once-daily versus twice-daily direct oral anticoagulants (DOAC) differs after atrial fibrillation(AF)-associated ischemic stroke is unclear. We explored this in a post-hoc analysis of ELAN trial data (NCT03148457). Patients and methods: We compared the risk of the primary outcome (recurrent ischemic stroke, systemic embolism, intracranial hemorrhage (ICH), major extracranial bleeding, vascular death) from treatment initiation to the trial’s 90-day follow-up in participants treated with once-daily or twice-daily DOAC after AF-associated stroke using Firth’s logistic and Cox proportional hazards regression in unadjusted, inverse-probability-of-treatment-weighted and augmented-inverse-probability-weighted models to address confounding. Secondary outcomes were the primary outcome components and non-major bleeding. We calculated the net clinical benefit (NCB) of twice-daily over once-daily DOAC by subtracting the weighted rate of excess bleeding attributable to twice-daily DOAC from the rate of excess ischemic events possibly prevented by twice-daily DOAC. Results: We analyzed 1890/2013 (94%) participants (median age 77 years, 45% female), of whom 384 (20%) received once-daily and 1506 (80%) twice-daily DOAC. The primary outcome occurred in 64 (3.4%) participants, and did not differ between DOAC types in logistic (OR unadjusted 0.89 (95% CI 0.50–1.66); OR weighted 1.34 (0.71–2.79); OR augmented 1.45 (0.81–3.21); twice-daily vs once-daily DOAC) nor in Cox models. We identified no clear differences in any secondary outcome. NCB analysis revealed a near-neutral net effect of twice-daily versus once-daily DOAC (+0.28 to +0.67 weighted events possibly prevented/100 person-months for ICH weights 1.5–3.3). Discussion and conclusion: The risk-benefit profile of once-daily versus twice-daily DOAC after AF-associated ischemic stroke does not seem to differ.
- 1 August 2025
- Published by Wolters Kluwer Health in Stroke
- Vol. 56 (8) , 2000-2008
Prior Reperfusion Strategy Does Not Modify Outcome in Early Versus Late Start of Anticoagulants in Patients With Ischemic Stroke: Prespecified Subanalysis of the Randomized Controlled ELAN Trial
BACKGROUND: Early initiation of direct oral anticoagulants (DOACs) in patients with nonvalvular atrial fibrillation and acute ischemic stroke is beneficial and safe. Whether prior acute reperfusion therapy modifies the treatment effect of early versus late DOAC initiation is unknown. METHODS: For this post hoc analysis of the multicenter, randomized controlled ELAN trial (Early Versus Late Initiation of Direct Oral Anticoagulants in Post-Ischaemic Stroke Patients With Atrial Fibrillation), all participants with data concerning reperfusion treatment were included. The primary outcome was the composite outcome of recurrent ischemic stroke, symptomatic intracranial hemorrhage, major extracranial bleeding, systemic embolism, or vascular death within 30 days. Patients were divided into 4 groups based on prior reperfusion therapy: no treatment, intravenous thrombolysis (IVT), endovascular treatment (EVT), or IVT combined with EVT. We performed logistic regression adjusted for age, hypertension, infarct location/size, pre-modified Rankin Scale, NIHSS, and hemorrhagic transformation, including the interaction term between treatment groups (early versus late DOAC) and reperfusion strategy. RESULTS: We included 1973 of 2013 (98%) patients of the ELAN trial population, with a median age of 77 (71–84) years and of whom 899 (46%) were female. Of them, 1015 (51%) underwent no prior reperfusion treatment, 519 (26%) IVT, 190 (10%) EVT, and 249 (13%) IVT+EVT. We did not identify an interaction for any of the outcome events between prior reperfusion therapy and timing of DOAC initiation. Rates were numerically lower in the early DOAC-initiated group for the following: no reperfusion therapy, 17 (3.3%) versus 24 (4.8%; adjusted odds ratio, 0.69 [95% CI, 0.36–1.28]); EVT, 1 (1.2%) versus 7 (6.4%; adjusted odds ratio, 0.25 [95% CI, 0.03–1.21]); and EVT+IVT, 3 (2.4%) versus 4 (3.3%; adjusted odds ratio, 0.76 [95% CI, 0.17–3.23]). In patients who had received IVT, the rates were 3% (n=8) in the early group versus 2% (n=5) in the late group (adjusted odds ratio, 1.52 [95% CI, 0.52–4.84]). CONCLUSIONS: Prior reperfusion therapy does not modify the effect of early versus late DOAC initiation on clinical outcomes in patients with atrial fibrillation and acute ischemic stroke. REGISTRATION: URL: https://www.clinicaltrials.gov ; Unique identifier: NCT03148457.
- 1 August 2025
- Published by Wolters Kluwer Health in Stroke
- Vol. 56 (8) , 2000-2008
Prior Reperfusion Strategy Does Not Modify Outcome in Early Versus Late Start of Anticoagulants in Patients With Ischemic Stroke: Prespecified Subanalysis of the Randomized Controlled ELAN Trial
BACKGROUND: Early initiation of direct oral anticoagulants (DOACs) in patients with nonvalvular atrial fibrillation and acute ischemic stroke is beneficial and safe. Whether prior acute reperfusion therapy modifies the treatment effect of early versus late DOAC initiation is unknown. METHODS: For this post hoc analysis of the multicenter, randomized controlled ELAN trial (Early Versus Late Initiation of Direct Oral Anticoagulants in Post-Ischaemic Stroke Patients With Atrial Fibrillation), all participants with data concerning reperfusion treatment were included. The primary outcome was the composite outcome of recurrent ischemic stroke, symptomatic intracranial hemorrhage, major extracranial bleeding, systemic embolism, or vascular death within 30 days. Patients were divided into 4 groups based on prior reperfusion therapy: no treatment, intravenous thrombolysis (IVT), endovascular treatment (EVT), or IVT combined with EVT. We performed logistic regression adjusted for age, hypertension, infarct location/size, pre-modified Rankin Scale, NIHSS, and hemorrhagic transformation, including the interaction term between treatment groups (early versus late DOAC) and reperfusion strategy. RESULTS: We included 1973 of 2013 (98%) patients of the ELAN trial population, with a median age of 77 (71–84) years and of whom 899 (46%) were female. Of them, 1015 (51%) underwent no prior reperfusion treatment, 519 (26%) IVT, 190 (10%) EVT, and 249 (13%) IVT+EVT. We did not identify an interaction for any of the outcome events between prior reperfusion therapy and timing of DOAC initiation. Rates were numerically lower in the early DOAC-initiated group for the following: no reperfusion therapy, 17 (3.3%) versus 24 (4.8%; adjusted odds ratio, 0.69 [95% CI, 0.36–1.28]); EVT, 1 (1.2%) versus 7 (6.4%; adjusted odds ratio, 0.25 [95% CI, 0.03–1.21]); and EVT+IVT, 3 (2.4%) versus 4 (3.3%; adjusted odds ratio, 0.76 [95% CI, 0.17–3.23]). In patients who had received IVT, the rates were 3% (n=8) in the early group versus 2% (n=5) in the late group (adjusted odds ratio, 1.52 [95% CI, 0.52–4.84]). CONCLUSIONS: Prior reperfusion therapy does not modify the effect of early versus late DOAC initiation on clinical outcomes in patients with atrial fibrillation and acute ischemic stroke. REGISTRATION: URL: https://www.clinicaltrials.gov ; Unique identifier: NCT03148457.
- 1 July 2025
- Published by Wolters Kluwer Health in Stroke
- Vol. 56 (7) , 1823-1831
Topographic Localization of Chronic Cerebellar Ischemic Lesions: Implications for Underlying Cause
BACKGROUND: Chronic cerebellar lesions of presumed ischemic origin are frequently found in patients with ischemic stroke and as incidental findings. However, the differentiation of embolic lesions from lesions caused by cerebral small vessel disease (SVD) is unclear. We aimed to investigate whether the location of chronic cerebellar ischemic lesions (deep versus cortical) indicates the underlying cause (embolic versus SVD). METHODS: This study was a post hoc data analysis from the multinational ELAN trial (Early Versus Late Initiation of Direct Oral Anticoagulants in Patients With Postischemic Stroke With Atrial Fibrillation), which included patients with acute ischemic stroke and atrial fibrillation cohort between 2017 and 2022. For comparison, data from 2 cohorts (DiViNAS [Disease Variability in NOTCH3-Associated SVD] and VASCAMY [Vascular and Amyloid Predictors of Neurodegeneration and Cognitive Decline in Nondemented Subjects]) consisting of participants with hereditary cerebral SVD (ie, cerebral autosomal dominant arteriopathy with subcortical infarcts and leukoencephalopathy) were analyzed (cerebral autosomal dominant arteriopathy with subcortical infarcts and leukoencephalopathy cohort). Brain magnetic resonance imaging scans were evaluated for presence and location of chronic cerebellar ischemic lesions. The association between these lesions and the severity of supratentorial SVD was analyzed using univariable and multivariable models, adjusting for key covariables. RESULTS: In the atrial fibrillation cohort (N=790), 278 (35%) patients had chronic cerebellar ischemic lesions (cortical: n=242; deep: n=36). In multivariable analyses, features of cerebral SVD were associated with deep cerebellar ischemic lesions (summary SVD score; odds ratio per point, 2.5 [95% CI, 1.5–3.5]; P P =0.107). In the cerebral autosomal dominant arteriopathy with subcortical infarcts and leukoencephalopathy cohort (N=257), chronic cerebellar ischemic lesions (n=108 [42%]) were almost exclusively identified in deep cerebellar regions (n=101, 94%). CONCLUSIONS: Chronic cerebellar ischemic lesions in deep but not cortical regions were associated with supratentorial cerebral SVD. Therefore, cerebral SVD is likely the primary cause of chronic ischemic lesions in deep cerebellar regions, while cortical cerebellar lesions are more likely attributable to embolic etiologies. REGISTRATION: URL: https://www.clinicaltrials.gov ; Unique identifier: NCT03148457.
- 1 July 2025
- Published by Wolters Kluwer Health in Stroke
- Vol. 56 (7) , 1823-1831
Topographic Localization of Chronic Cerebellar Ischemic Lesions: Implications for Underlying Cause
BACKGROUND: Chronic cerebellar lesions of presumed ischemic origin are frequently found in patients with ischemic stroke and as incidental findings. However, the differentiation of embolic lesions from lesions caused by cerebral small vessel disease (SVD) is unclear. We aimed to investigate whether the location of chronic cerebellar ischemic lesions (deep versus cortical) indicates the underlying cause (embolic versus SVD). METHODS: This study was a post hoc data analysis from the multinational ELAN trial (Early Versus Late Initiation of Direct Oral Anticoagulants in Patients With Postischemic Stroke With Atrial Fibrillation), which included patients with acute ischemic stroke and atrial fibrillation cohort between 2017 and 2022. For comparison, data from 2 cohorts (DiViNAS [Disease Variability in NOTCH3-Associated SVD] and VASCAMY [Vascular and Amyloid Predictors of Neurodegeneration and Cognitive Decline in Nondemented Subjects]) consisting of participants with hereditary cerebral SVD (ie, cerebral autosomal dominant arteriopathy with subcortical infarcts and leukoencephalopathy) were analyzed (cerebral autosomal dominant arteriopathy with subcortical infarcts and leukoencephalopathy cohort). Brain magnetic resonance imaging scans were evaluated for presence and location of chronic cerebellar ischemic lesions. The association between these lesions and the severity of supratentorial SVD was analyzed using univariable and multivariable models, adjusting for key covariables. RESULTS: In the atrial fibrillation cohort (N=790), 278 (35%) patients had chronic cerebellar ischemic lesions (cortical: n=242; deep: n=36). In multivariable analyses, features of cerebral SVD were associated with deep cerebellar ischemic lesions (summary SVD score; odds ratio per point, 2.5 [95% CI, 1.5–3.5]; P P =0.107). In the cerebral autosomal dominant arteriopathy with subcortical infarcts and leukoencephalopathy cohort (N=257), chronic cerebellar ischemic lesions (n=108 [42%]) were almost exclusively identified in deep cerebellar regions (n=101, 94%). CONCLUSIONS: Chronic cerebellar ischemic lesions in deep but not cortical regions were associated with supratentorial cerebral SVD. Therefore, cerebral SVD is likely the primary cause of chronic ischemic lesions in deep cerebellar regions, while cortical cerebellar lesions are more likely attributable to embolic etiologies. REGISTRATION: URL: https://www.clinicaltrials.gov ; Unique identifier: NCT03148457.